ClinicalTrials.gg
CompletedNCT06109831Updated Feb 2, 2026

Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemic

A Phase 2 interventional study of SHR-1918 and SHR-1918 placebo in Hyperlipidemic, sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-02-02.

Sponsored by Beijing Suncadia Pharmaceuticals Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
335
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a Multicenter, Randomized, Double-Blind, Placebo-Parallel-Controlled, Phase II Clinical Stud to assess the reduction of low-density lipoprotein cholesterol (LDL-C) by SHR-1918 in patients with Hyperlipidemic.

02

Conditions studied

  • Hyperlipidemic
03

In context

Lead sponsor

Beijing Suncadia Pharmaceuticals Co., Ltd is the lead sponsor of 25 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Regularly taking any moderate-intensity or higher dose* of statin stabilization therapy for ≥4 weeks at screening:

    1. ASCVD risk is ultra-high risk Fasting LDL-C ≥ 1.4 mmol/L;
    2. ASCVD risk very high risk Fasting LDL-C ≥1.8 mmol/L;
    3. ASCVD risk is intermediate or high risk Fasting LDL-C ≥ 2.6 mmol/L.
  2. Any other condition that is not met at screening Regularly taking any moderate intensity and higher dose* statin stabilization therapy for ≥4 weeks;

    a) Fasting LDL-C ≥ 2.6 mmol/L.

  3. Fasting triglycerides ≤ 5.6 mmol/L.

Exclusion criteria

Exclusion Criteria:

  1. Previously diagnosed type 1 diabetes or poorly controlled type 2 diabetes at screening ( > 8.5%).
  2. \<30ml/min/1.73m2 at the screening visit.
  3. CK >5times at the screening visit.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
335 participants (actual)

Study arms

  • Experimental
    SHR-1918

    Drug: SHR-1918

  • Placebo comparator
    SHR-1918 placebo

    Drug: SHR-1918 placebo

Interventions

  • SHR-1918

  • DrugSHR-1918 placebo

    SHR-1918 placebo

06

What researchers measure

Primary outcomes

  1. Percent change in calculated LDL-C from baseline to week 16

    Time frame: from baseline to week 16

Secondary outcomes

  1. Change in calculated LDL-C from baseline to week 16

    Time frame: from baseline to week 16

07

Study locations

1 site
  • The Second Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310009, China
08

References and documents

Publications

  • Xie X, Shi X, Zhang Y, Su S, Jiang C, Miao L, Wang J, Peng D, Lv L, Chai X, Luo S, Zheng Y, Huang S, Zhu D, Liao S, Ren M, Gao X, Yang H, Zhou H, He Y, Han Y, Xu J, Zhang L, Du L, Yao Z, Sheng J, Peng X, Chen X, Li J, Mi J, Lu Q, Wang H, Shen Z, Zhao Z, Gao F, Lv C, Zhu M, Zhu Y, Wang J. Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study. J Am Coll Cardiol. 2025 May 20;85(19):1821-1835. doi: 10.1016/j.jacc.2025.03.008. Epub 2025 Mar 31. PubMed 40167414 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Jul 2025, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2023
First posted
Oct 31, 2023
StartActual
Nov 24, 2023
Primary completionActual
Jul 4, 2025
CompletionActual
Jul 4, 2025
Last update
Feb 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06109831
Responsible party
Sponsor
First posted
Oct 31, 2023
Start date
Nov 24, 2023
Primary completion
Jul 4, 2025
Completion
Jul 4, 2025
Last update
Feb 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1918

Start the discussion